Clinical Trials Sponsored by UniQure N.V.

Total 1483 results

Terumo Europe N.V.

Completed

Treatment of Patients With Lesions in the Superficial Femoral and/ or Popliteal Arteries Using Kanshas Paclitaxel-coated Balloon Catheter. (KANSHAS-1)

Peripheral Artery Disease | Femoropopliteal Occlusive Disease

Belgium, Germany
Terumo Europe N.V.

Completed

Prospective Single Arm CAS - ROADSAVER Study (ROADSAVER)

Carotid Artery Stenosis

Belgium, Spain, Czechia, France, Serbia, Netherlands, Germany, Hungary, North Macedonia, Latvia, Poland, Portugal, Slovakia
Sequana Medical N.V.

Active, not recruiting

Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study) (POSEIDON)

Ascites

United States, Canada
Sequana Medical N.V.

Active, not recruiting

Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion (SAHARA)

Heart Failure | Volume Overload

Georgia
Terumo Europe N.V.

Completed

Post-Market Clinical Investigation of the FemoSeal™ VCS: A Prospective, Multi-Center Observational European Study (FEMOSEAL CLOSE)

Peripheral Vascular Disease | Hemostasis | Vascular Closure | Endovascular Procedure

Belgium, France, Germany
Terumo Europe N.V.

Withdrawn

BioPearl™ Microspheres Loaded With Doxorubicin: Prospective, Single Arm, Multi-centre Post-market Follow-up Study. (BIOPEARL-FIRST)

Hepatocellular Carcinoma

Belgium
Octimet Oncology N.V.

Terminated

OMO-1 in Solid Malignancies

Neoplasms

France, United Kingdom, Netherlands, United States, Belgium
Terumo Europe N.V.

Completed

LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry)

Hepatocellular Carcinoma

Belgium, France
Terumo Europe N.V.

Terminated

Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry (Iberis)

Resistant Hypertension

Serbia, Spain
Sequana Medical N.V.

Terminated

Alfapump-albumin Replacement Therapy

Liver Cirrhosis

United Kingdom
Sequana Medical N.V.

Completed

Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites

Malignant Ascites

Germany, Switzerland, United Kingdom
Sequana Medical N.V.

Terminated

Investigation Into the Automated Drainage of Recurrent Effusions From the Pleural Space in Thoracic Malignancy. (ADEPT)

Pleural Effusion

France, United Kingdom
Terumo Europe N.V.

Unknown

Rapid Exchange Devices Observational Registry. (RXRegistry)

Peripheral (Lowr Extremity) Arterial Disease.

Spain, Belgium
Terumo Europe N.V.

Completed

Randomized Study to Assess the Effect of ThRombus Aspiration on Flow Area in STEMI Patients (TROFI)

Myocardial Infarction | Coronary Artery Disease | STEMI

Germany, France, Denmark, Netherlands
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma (MoMMent)

Relapsed/Refractory Multiple Myeloma

Germany, Italy, Belgium, Spain, Netherlands, France, United Kingdom
Janssen Pharmaceutica N.V., Belgium

Active, not recruiting

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice (PsABIOnd)

Arthritis, Psoriatic

United Kingdom, Korea, Republic of, France, Belgium, Japan, Taiwan, Austria, Canada, Netherlands, Spain, Italy, Germany, Australia, Switzerland, Mexico, Sweden, Greece, Argentina, Colombia, Russian Federation
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

Critical Confirmed Coronavirus Disease (COVID)-19

United States
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy (COSMOS)

Arthritis, Psoriatic

Belgium, France, Israel, Italy, Germany, Bulgaria, Spain, Poland, Russian Federation, United Kingdom, Ukraine, Hungary, Portugal, Greece
Janssen Pharmaceutica N.V., Belgium

Completed

A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants

Healthy

Belgium
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents

Healthy

Netherlands
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants (AQUARiUS)

Prostatic Neoplasms

France, United Kingdom, Denmark
Janssen Pharmaceutica N.V., Belgium

Completed

Tracking Biologics Along the Silk Road (HARIR)

Arthritis, Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic; Colitis, Ulcerative

Saudi Arabia, Egypt, Qatar, Algeria, Kuwait
Janssen Cilag N.V./S.A.

Completed

IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation

Psychomotor Agitation | Acute Disease

Belgium
Janssen Pharmaceutica N.V., Belgium

Completed

Clinical Assessment and Psychosocial Impact of Psoriasis (EPIDEPSO)

Psoriasis

France, United Kingdom, Spain, Belgium, Israel, Netherlands, Greece, South Africa, Russian Federation, Ireland, Austria, Norway
Vivoryon Therapeutics N.V.
Covance

Completed

Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole

Healthy Volunteers | Pharmacologic Action

United Kingdom
Janssen Cilag N.V./S.A.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants

Healthy Volunteers

United Kingdom
Janssen Pharmaceutica N.V., Belgium

Completed

The Prolonged Use of Topiramate for Preventing Migraine Headaches (PROMPT)

Migraine

France, Poland, United Kingdom, Belgium, Germany, Spain, Portugal, Slovenia, Bulgaria, Saudi Arabia, Switzerland, Denmark, Greece, Russian Federation, Turkey, Hungary, Austria, Ireland, Norway, Czech Republic
Janssen Pharmaceutica N.V., Belgium

Terminated

The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients

Schizophrenia | Cognition Disorders | Alzheimer's Disease

Germany
Janssen Cilag N.V./S.A.

Completed

An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone (e-STAR)

Schizophrenia
Janssen Pharmaceutica N.V., Belgium

Completed

The Effectiveness and Safety of Topiramate on Prevention of Chronic Migraine

Migraine
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation

Conduct Disorder | Oppositional Defiant Disorder | Disruptive Behavior Disorder
Janssen Pharmaceutica N.V., Belgium

Completed

A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia

Psychotic Disorders | Schizophrenia
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, in Patients With Rheumatoid Arthritis or Osteoarthritis

Arthritis | Osteoarthritis | Rheumatoid Arthritis
Janssen Pharmaceutica N.V., Belgium

Completed

Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.

Female Contraception | Contraception
Janssen Pharmaceutica N.V., Belgium

Withdrawn

A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment (SALMONS)

Hepatitis B, Chronic

Germany, France, Italy, Spain, Denmark, Portugal, Greece
Janssen Pharmaceutica N.V., Belgium

Completed

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

HIV-1

United States, Spain
Janssen Pharmaceutica N.V., Belgium

Completed

A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis (PsaBio)

Psoriatic Arthritis

France, United Kingdom, Belgium, Spain, Netherlands, Greece, Russian Federation
Janssen Pharmaceutica N.V., Belgium

Terminated

A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants

Renal Impairment

Germany
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal Function

Renal Insufficiency

Germany
Janssen Cilag N.V./S.A.

Completed

Study to Investigate Effects of Repeated Administration of Itraconazole on Pharmacokinetics of JNJ-42847922 in Healthy Male Participants

Healthy

Germany
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.

Pain

France, Poland, Germany, Slovenia, Sweden, Czech Republic, Norway, Slovakia, Switzerland, Denmark
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder

Bipolar Disorder

China, Taiwan, Colombia, India, Malaysia, Russian Federation, South Africa, Greece, Peru, Germany, Mexico, Lebanon, Indonesia, Philippines, Jordan
Janssen Cilag N.V./S.A.

Completed

A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode

Schizophrenia

South Africa
Janssen Pharmaceutica N.V., Belgium

Completed

Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode

Schizophrenia

United Kingdom, Slovenia, Denmark, Finland, France, Greece, Israel, Norway, Sweden, Switzerland
Janssen Pharmaceutica N.V., Belgium

Completed

Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine (DDI Coartem)

HIV
Janssen Pharmaceutica N.V., Belgium

Completed

A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's Disease

Mental Disorders | Brain Diseases | Nervous System Diseases | Dementia | Alzheimer Disease
Janssen Pharmaceutica N.V., Belgium

Completed

A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis

Schizophrenia
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)

Psychotic Disorders | Schizophrenia
Janssen Pharmaceutica N.V., Belgium

Completed

Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

Dementia | Alzheimer Disease
Janssen Pharmaceutica N.V., Belgium

Completed

A 15-day Study to Assess the Safety and Clinical Utility of Duragesic (Fentanyl Transdermal Patch) in the Treatment of Children With Continuous Pain Requiring Narcotic Pain Relief Therapy

Chronic Pain

3

Subscribe